Immune globulin subcutaneous, human – klhw 20% solution (Xembify®, IGSC-C 20%) has a positive safety and tolerability profile in an open-label, multicenter, phase 3 study in primary immunodeficiency (PI)

This trial assessed the safety and tolerability of IGSC-C 20% and intravenous immune globulin infusion (human),10% caprylate/chromatography purified (IGIV-C 10%) in participants with PI.

Source: Journal of Allergy and Clinical Immunology - January 31, 2020 Category: Allergy & Immunology Authors: H. James Wedner, John Sleasman, William Lumry, Iftikhar Hussain, James Harris, Elsa Mondou, Jiang Lin, Carrie Hames, Montse Querolt, Mark Stein Source Type: research